CNN reports on Acthar : doctor payments, paid prescribers, drug sales and pricing
“More than 80% of doctors who filed Medicare claims in 2016 for H.P. Acthar Gel — a drug best known for treating a rare infant seizure disorder — received money or other perks from the drugmakers, according to a CNN analysis of publicly identified prescribers.
The analysis, which looked at doctors who filed more than 10 Part D claims, found that the drugmakers — Mallinckrodt and Questcor — paid 288 prescribers more than $6.5 million for consulting, promotional speaking and other Acthar-related services between 2013 and 2016. Mallinckrodt purchased Questcor in 2014.
At about the same time, Medicare spending on Acthar rose dramatically — more than tenfold over six years.”
… continue reading about Acthar and doctor payments, paid prescribers, drug sales and pricing on CNN.
Thanks to DES Daughter Caitlin McCarthy suggestion tweet, DES and the transgenerational effects of endocrine disruptors made the list of the “97 issues you care about most” . John D. Sutter, a columnist for CNN Opinion, is now asking people to VOTE on what he will cover as part of the Change the List project. Grasp this opportunity to tell CNN you want more media coverage of the DES tragedy!
Elevated risk for this type of cancer in DES Daughters as they age
DES and Cancer: the Never Ending Story
41 years ago, a connection between DES exposure and cancer in DES daughters was established. Cases of Clear Cell Adenocarcinoma (CCA) of the vagina were diagnosed in an age group never before found to develop it. At the time the peak incidence of CCA in DES Daughters was in the late teens and early 20s. Most young women with CCA of the vagina have a history of prenatal exposure to diethylstilbestrol (DES). DES daughters were told by physicians that the risk was low when you reach your 30s and you can still read today on some websites that “if a DES daughter has not developed this cancer by age 30, she will not develop it”.
But today, DES daughters cancer fears are confirmed and justified as the findings and conclusions of a new report by CDC researchers suggest an elevated risk for this vaginal/cervical cancer in DES Daughters as they age.
When researchers first linked prenatal DES exposure to vaginal / cervical cancer in a small group of women, soon after, the Food and Drug Administration (FDA) notified physicians throughout the U.S.A. that DES should not be prescribed to pregnant women (note that it wasn’t banned!). In Europe, the drug continued to be prescribed to pregnant women until 1978. So even though this report says “elevated risk among women born between 1947 and 1971 in the United States”, it should read “among all women born between 1947 and 1978 in countries where DES was prescribed”. In the United States alone it is estimated that five to 10 million people were exposed to DES between 1938 and 1971.
When will this stop? The statement “The more I learn the less I know” really seems to apply to the DES tragedy. As we learn more about the devastating health effects of diethylstibestrol, we begin to become more aware of the limits of our knowledge regarding the long term effects not only for DES daughters but also DES sons and the DES 3rd generation (children of DES daughters and sons). DES truly is a never ending story!
Wherever you are stay safe and remind your GP that DES daughters need yearly Pap test and pelvic exam as well as regular health screening and adequate care!